The first nasal vaccine against coronavirus developed by Bharat Biotech supported by Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) has been given regulator’s nod for conducting phase 2 and 3 trials, the Ministry of Science & Technology informed on Friday.
Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.
“Bharat Biotech’s intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials,” the DBT said.
This is the first of its kind COVID-19 jab to undergo human clinical trials in India.
ALSO READ | Single-dose Sputnik Light vaccine set for launch in September, likely to be priced at Rs 750: Report
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
Bharat Biotech has in-licensed technology from Washington University in St Louis, US.
(With PTI inputs)
ALSO READ | SII chairman Poonawalla against using cocktail of COVID-19 vaccines
Latest India News